首页> Lung cancer: Journal of the International Association for the Study of Lung Cancer> Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer

导出原文传递

翻译打印收藏纠错

第一作者： Luis G. Paz-Ares

作者： Luis G. Paz-Ares ^[1] ; Maurice Pérol ^[2] ; Tudor-Eliade Ciuleanu ^[3] ; Ruben Dario Kowalyszyn ^[4] ; Martin Reck ^[5] ; Conrad R. Lewanski ^[6] ; Konstantinos Syrigos ^[7] ; Oscar Arrieta ^[8] ; Kumar Prabhash ^[9] ; Keunchil Park ^[10] ; Joanna Pikiel ^[11] ; Tuncay G?ksel ^[12] ; Pablo Lee ^[13] ; Anna Zimmermann ^[14] ; Gebra Cuyun Carter ^[15] ; Ekaterine Alexandris ; Edward B. Garon

作者单位： Oncology Unit GPP, Sotiria General Hospital, Athens School of Medicine ^[1] Eli Lilly and Company ^[2] Eli Lilly and Company, Bridgewater ^[3] Département de Cancérologie Médicale, Centre Léon Bérard ^[4] Charing Cross Hospital ^[5] Samsung Medical Center, Sungkyunkwan University School of Medicine ^[6] Ege University Faculty of Medicine ^[7] David Geffen School of Medicine at UCLA/Translational Research in Oncology-US Network ^[8] Instituto Nacional de Cancerología (INCan) ^[9] Wojewódzkie Centrum Onkologii ^[10] Institute of Oncology Prof. Dr. Ion Chiricu?? and University of Medicine and Pharmacy Iuliu Ha ^[11] Tata Memorial Centre ^[12] Hospital Universitario Doce de Octubre ^[13] LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research ^[14] Centro de Investigaciones Clínicas ^[15]

关键词 Non-small-cell lung cancer Histology Ramucirumab Docetaxel

发布时间 2018-05-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交